创伤性颅内出血患者早期静脉血栓栓塞预防:前瞻性多中心创伤性血栓栓塞领导者联盟研究分析
该研究为前瞻性多中心创伤性血栓栓塞领导者联盟研究的二次分析,纳入头部简明损伤定级评分>2且因颅内出血立即暂停VTE预防的患者881例,其中378例(43%)在48小时内启动VTE预防(早期组)。与晚期组(>48小时)相比,早期组总体VTE发生率(7.2% vs 12.4%,p=0.01)和深静脉血栓发生率(6.1% vs 11.0%,p=0.01)更低,而肺栓塞(2.2% vs 2.1%,p=0.94)、颅内出血进展(1.8% vs 1.9%,p=0.95)及其他出血事件(3.0% vs 1.9%,p=0.28)无显著差异。多因素分析显示,VTE预防>48小时(OR 1.86)、机械通气>3天(OR 2.00)和风险评分≥5分(OR 6.70)为VTE独立危险因素,使用依诺肝素与VTE降低相关(OR 0.54)。作者认为,对严重创伤性脑损伤患者,依诺肝素优于普通肝素。
要点
- 创伤性颅内出血患者48小时内启动VTE预防(早期组378例,43%)与晚期组(>48小时)相比,总体VTE发生率7.2% vs 12.4%(p=0.01),DVT发生率6.1% vs 11.0%(p=0.01)。
- 早期VTE预防未增加颅内出血进展(1.8% vs 1.9%,p=0.95)及其他出血事件(3.0% vs 1.9%,p=0.28)风险。
- 多因素分析显示,VTE预防>48小时(OR 1.86)、机械通气>3天(OR 2.00)和风险评分≥5分(OR 6.70)为VTE独立危险因素(均p<0.05)。
- 使用依诺肝素进行VTE预防与VTE降低相关(OR 0.54,p<0.05),作者认为对严重创伤性脑损伤患者依诺肝素优于普通肝素。
适用人群与场景
- 头部简明损伤定级评分>2分且因颅内出血立即暂停VTE预防的创伤患者,共881例。
诊断标准与关键阈值
- 头部简明损伤定级评分>2分;因颅内出血立即暂停VTE预防。
- 早期VTE预防定义为开始时间≤48小时,晚期为>48小时。
- 风险评分≥5分为VTE独立危险因素(OR 6.70,p<0.05)。
处置流程与药物剂量
- 对于创伤性颅内出血患者,可考虑在48小时内启动VTE预防(早期组378例,43%)。
- 依诺肝素用于VTE预防与VTE降低相关(OR 0.54,p<0.05),作者认为对严重创伤性脑损伤患者依诺肝素优于普通肝素。
研究设计与关键结果
- 研究设计:前瞻性多中心创伤性血栓栓塞领导者联盟研究的二次分析;样本量881例;人群为头部简明损伤定级评分>2分且因颅内出血暂停VTE预防的创伤患者;早期组(≤48小时)378例(43%),晚期组(>48小时)503例。
- 主要终点:晚期组VTE发生率12.4% vs 早期组7.2%(p=0.01);晚期组DVT发生率11.0% vs 早期组6.1%(p=0.01)。
- 次要终点:肺栓塞发生率早期组2.2% vs 晚期组2.1%(p=0.94);颅内出血进展早期组1.8% vs 晚期组1.9%(p=0.95);其他出血事件早期组3.0% vs 晚期组1.9%(p=0.28)。
- 多因素logistic回归:VTE预防>48小时(OR 1.86)、机械通气>3天(OR 2.00)、风险评分≥5分(OR 6.70)为VTE独立危险因素(均p<0.05);使用依诺肝素与VTE降低相关(OR 0.54,p<0.05)。
- 早期VTE预防(≤48小时)与颅内出血进展(OR 0.75)或其他出血事件风险(OR 1.28)无关(均p=NS)。
证据类型、等级与局限
- 证据类型:前瞻性多中心研究的二次分析;证据等级:治疗/护理管理;Level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于创伤性颅内出血患者,早期(≤48小时)启动VTE预防与VTE/DVT发生率降低相关,且不增加颅内出血进展或其他出血事件风险。
- 作者认为,对严重创伤性脑损伤患者,依诺肝素优于普通肝素作为VTE预防。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal time to initiate venous thromboembolism prophylaxis (VTEp) for patients with intracranial hemorrhage (ICH) is controversial and must balance the risks of VTE with potential progression of ICH. We sought to evaluate the efficacy and safety of early VTEp initiation after traumatic ICH.
METHODS: This is a secondary analysis of the prospective multicenter Consortium of Leaders in the Study of Thromboembolism study. Patients with head Abbreviated Injury Scale score of > 2 and with immediate VTEp held because of ICH were included. Patients were divided into VTEp ≤ or >48 hours and compared. Outcome variables included overall VTE, deep vein thrombosis (DVT), pulmonary embolism, progression of intracranial hemorrhage (pICH), or other bleeding events. Univariate and multivariate logistic regressions were performed.
RESULTS: There were 881 patients in total; 378 (43%) started VTEp ≤48 hours (early). Patients starting VTEp >48 hours (late) had higher VTE (12.4% vs. 7.2%, p = 0.01) and DVT (11.0% vs. 6.1%, p = 0.01) rates than the early group. The incidence of pulmonary embolism (2.1% vs. 2.2%, p = 0.94), pICH (1.9% vs. 1.8%, p = 0.95), or any other bleeding event (1.9% vs. 3.0%, p = 0.28) was equivalent between early and late VTEp groups. On multivariate logistic regression analysis, VTEp >48 hours (odds ratio [OR], 1.86), ventilator days >3 (OR, 2.00), and risk assessment profile score of ≥5 (OR, 6.70) were independent risk factors for VTE (all p < 0.05), while VTEp with enoxaparin was associated with decreased VTE (OR, 0.54, p < 0.05). Importantly, VTEp ≤48 hours was not associated with pICH (OR, 0.75) or risk of other bleeding events (OR, 1.28) (both p = NS).
CONCLUSION: Early initiation of VTEp (≤48 hours) for patients with ICH was associated with decreased VTE/DVT rates without increased risk of pICH or other significant bleeding events. Enoxaparin is superior to unfractionated heparin as VTE prophylaxis in patients with severe TBI.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
参考来源
- Wu YT, Chien CY, Matsushima K, et al. Early venous thromboembolism prophylaxis in patients with trauma intracranial hemorrhage: Analysis of the prospective multicenter Consortium of Leaders in Traumatic Thromboembolism study. J Trauma Acute Care Surg. 2023. PMID: 37314427. doi:10.1097/TA.0000000000004007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。